New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
10:49 EDTODP, NAVB, RAD, AVEO, AMATHigh option volume stocks; ODP, NAVB, RAD, AVEO, AMAT
News For ODP;NAVB;RAD;AVEO;AMAT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
06:12 EDTAMATKLA-Tencor removed from Focus List at Citigroup
Subscribe for More Information
October 21, 2014
08:03 EDTRADCVS offering drug plan with higher co-pay at stores selling tobacco, WSJ says
CVS Health (CVS), which stopped selling tobacco products last month, is now offering a prescription-drug plan via its pharmacy benefits unit Caremark that charges patients copayments that are up to $15 higher on prescriptions filled where tobacco is sold, which includes at rival pharmacies operated by Walgreen (WAG) and Rite-Aid (RAD), reported The Wall Street Journal. Reference Link
October 20, 2014
09:01 EDTODPOffice Depot stores now accept Apple Pay
Subscribe for More Information
October 16, 2014
09:32 EDTODPOffice Depot: European restructuring plan includes reduction of 1,100 positions
Subscribe for More Information
07:54 EDTAMATApplied Materials weakness creates buying opportunity, says Stifel
Stifel believes that Applied Materials' (AMAT) fundamental story has not changed, while the weakness in the shares is an overreaction to certain issues, including the Microchip (MCHP) preannouncement. Stifel expects the company to benefit from strong WFE spending in 2015 and increasing capital intensity trends in the chip sector. The firm keeps a $25 price target and Buy rating on the shares.
October 15, 2014
10:02 EDTAMATOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:20 EDTNAVBOn The Fly: Pre-market Movers
Subscribe for More Information
08:03 EDTNAVBNavidea names Gonzalez CEO
Subscribe for More Information
08:01 EDTNAVBNavidea names Gonzalez CEO
07:39 EDTAMATApplied Materials upgraded at BofA/Merrill
Subscribe for More Information
07:03 EDTNAVBNavidea announces FDA sNDA approval for Lymphoseek extended use
Navidea Biopharmaceuticals announced that the U.S. Food and Drug Administration has approved the Supplemental New Drug Application for the expanded use of Lymphoseek injection for lymphatic mapping in solid tumors and adding Sentinel Lymph Node detection for breast cancer and melanoma to the approved indications. The FDA also allowed expanded utilization of Lymphoseek with or without scintigraphic imaging to enable pre-operative imaging and mapping of lymph nodes to facilitate node localization during surgical procedures. Lymphoseek will be immediately available using existing reimbursement codes for this expanded population of cancer patients. In the approval action letter, the FDA also outlined a post-marketing requirement for initiation of a pediatric study in solid tumor cancer with a target date for submission in 2018.
06:15 EDTAMATApplied Materials upgraded to Buy from Neutral at BofA/Merrill
06:08 EDTAMATApplied Materials implied volatility of 47 at upper end of index mean range
Subscribe for More Information
October 13, 2014
10:08 EDTRADOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:47 EDTRADRite Aid initiated with a Market Perform at Cowen
Subscribe for More Information
October 10, 2014
11:27 EDTAMATApplied Materials falls with peers, bearish double top active
Subscribe for More Information
11:13 EDTAMATMicrochip not relevant to DRAM, NAND, says Summit Research
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use